Indications |
Intravenous Muscle relaxant in general anaesthesia Adult: As chloride: single dose of 0.3-1.1 mg/kg injected; supplementary doses of 50-100% of the initial dose may be given at 5-10 min intervals. Max dose (repeated IV injection or continuous infusion): 500 mg/hr Child: As chloride: <1 yr: 2 mg/kg; 1-12 yr: 1 mg/kg. Intramuscular Muscle relaxant in general anaesthesia Adult: As chloride: 3-4 mg/kg. Max total dose: 150 mg Child: As chloride: <1 yr: Up to 4-5 mg/kg; ≥1 yr: Up to 4 mg/kg. Max dose: 150 mg. Reconstitution: IV infusion: dilute to a concentration of 1-2 mg/ml (0.1-0.2%) with 5% dextrose, 5% dextrose and 0.9% sodium chloride, 0.9% sodium chloride, (1/6) M sodium lactate; given at a rate 0.5-10 mg/min depending on the response and requirements of patient. Incompatibility: Alkaline solutions with pH>8.5 . |
Contraindications |
Genetic disorders of plasma pseudocholinesterase, personal/family history of malignant hyperthermia, hypersensitivity from previous neuromuscular drug, severe burns, massive trauma, extensive denervation of skeletal muscle, patients with risk of hyperkalaemia, renal impairment, angle closure glaucoma. |
Warnings / Precautions |
Bone fracture, raised intraocular pressure, neuromuscular disease, infants, childn, adolescents, pregnancy and lactation. |
Adverse Reactions |
Bradycardia, tachycardia, hypotension, hyperpertension, raised intraocular pressure, hyperkalaemia, excessive salivation. Potentially Fatal: Respiratory depression, dysrhythmias, rhabdomyolsis, malignant hyperthermia. |
Drug Interactions |
Concurrent use with anticholinesterases, cyclophosphamide, antiarrhythmics, aminoglycosides, lincosamides (clindamycin and lincomycin), anticonvulsants, phenelzine, magnesium, metoclopramide, inhalation anaesthetics, exposure to organophosphate insecticides may enhance neuromuscular block of suxamethonium. Increased risk of arrhythmias with cardiac glycosides. See Below for More suxamethonium chloride Drug Interactions |
Mechanism of Actions |
Suxamethonium chloride is an ultrashort-acting depolarising type skeletal muscle relaxant. It blocks the neuromuscular junction by binding to the cholinergic receptors and depolarising it. Onset: IV: 30-60 sec; IM: 2-3 min Duration: IV: 2-6 min; IM: 10-30 min Distribution: Small amounts of suxamethonium cross the placenta Metabolism: Rapidly hydrolysed by plasma cholinesterase. Excretion: 10% excreted unchanged in urine. |
Storage Conditions |
Intramuscular: Refrigerate at 2-8°C. Intravenous: Refrigerate at 2-8°C. |
Storage |
Intramuscular: Refrigerate at 2-8°C. Intravenous: Refrigerate at 2-8°C. |
Available As |
|
Suxamethonium Chloride
Post Review about Suxamethonium Chloride Click here to cancel reply.
Suxamethonium Chloride Containing Brands
Suxamethonium Chloride is used in following diseases
Drug - Drug Interactions of Suxamethonium Chloride
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.